Shares of 10x Genomics, Inc. (TXG) soared by 5.04% on Thursday, October 11, 2024, as investors remained optimistic about the company's growth prospects despite a weaker-than-expected revenue guidance for the third quarter.
The stock rally came after an analysis by Simply Wall St highlighted that TXG's price-to-sales ratio had returned to a level more in line with the broader life sciences industry. The report noted that TXG's revenue growth has outpaced the industry average, with a 56% increase over the past three years, including an 11% rise in the previous year.
While analysts expect TXG's revenue growth to moderate to 8.6% annually over the next three years, this figure is still slightly higher than the industry's projected growth rate of 7%. According to the report, investors appear comfortable with TXG's valuation and growth trajectory, as reflected in the stock's price-to-sales ratio.
However, TXG also announced on Thursday that its third-quarter revenue is expected to be around $151.7 million, down 1% from the year-ago period. This weaker-than-expected guidance initially weighed on the stock, but investors ultimately focused on the company's overall growth potential and reasonable valuation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.